Kevin Sullivan

Kevin is fighting infection for the team.
We’re happy to be on his defensive line.

Appili Therapeutics CEO Kevin Sullivan and his team are developing new ways to fight infectious disease, still the leading cause of death worldwide.

Today the company is focused on two drugs. The first removes the awful taste from an existing antibiotic that treats a serious stomach infection known as C-difficile in children. Kids are obviously more willing to take a better-tasting drug, making the treatment more effective.

Appili Therapeutics Receives Government of Canada Support for Development of New Antibiotic to Treat Gram-Negative Infections

Appili Therapeutics Inc. (Appili), an anti-infective drug development company, announced today it will be receiving an additional $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP), bringing IRAP support for this project to a total of up to $759,000.

Business Over Breakfast – Entrepreneurship & Investment: A Personal View with Permjot Valia

Permjot Valia: angel investor, fund manager and post-secondary educator (and we’d consider him an entrepreneur, too!). Bringing a local and international perspective on entrepreneurship and investment to the table, Permjot will offer insights based on his experience in the world of start-ups. You can watch a stream of this session on our YouTube channel.


Subscribe to Innovacorp RSS